Drugs / FTC/TDF
last change Mar 2018 re-read 2 minutes ago

FTC/TDF

Developed for
HIV infectious disease

Trials 0

Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT02616783 Comparator Dec 2015 → Feb 2018 HIV infectious disease Gilead Sciences Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as FTC/TDF ClinicalTrials.gov intervention name — accepted as the source's own label NCT02616783
Route Oral “200/300 mg tablet administered orally once daily” NCT02616783